Bone health

Osteoporosis therapy should be tailored to age: endocrinologist

Careful selection of osteoporosis therapy is needed in younger patients who may at risk of a rebound rise in fractures after stopping long term treatment with agents such as denosumab, an endocrinologist says. Patients who stop the anti-RANKL agent denosumab after many years of treatment show accelerated bone loss and a corresponding rise in fracture ...

Already a member?

Login to keep reading.

© 2021 the limbic